| AIF | anemia-inducing factor; anti-inflammatory; anti-invasion factor |
|---|---|
| BCF | basophil chemotactic factor; bioconcentration factor; breast cyst fluid |
| BPF | bradykinin-potentiating factor; bronchopulmonary fistula; burst-promoting factor |
| CCF | cancer coagulation factor; cardiolipin complement fixation; carotid-cavernous fistula; centrifuged c... |
| CMF | calcium-magnesium free; catabolite modular factor; chondromyxoid fibroma; Christian Medical Fellowsh... |
| direct lytic factor of cobra venom | A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent. Synonym: cobra toxin, direct lytic factor of cobra venom. (05 Mar 2000) |
|---|---|
| Duran-Reynals permeability factor | <enzyme> Enzyme that degrades hyaluronic acid, found in lysosomes. (18 Nov 1997) |
| duty factor | <radiobiology> Ratio of the duration of time when a system is actually operating to the total time for a complete cycle of the system. For example: if a tokamak experiment runs for 5 seconds and then sits for 500 seconds while the power supplies are recharged, then the duty factor is 1%. Similar to capacity factor for powerplants. Synonym: duty cycle. (09 Oct 1997) |
| q-factor | <radiobiology> Ratio of power produced by fusion to power put into the reactor to heat the plasma and drive the magnetic fields. Q = 1 is the definition of scientific breakeven, where power out = power in. Economical fusion will require Q significantly greater than 1. Fortunately Q increases dramatically as the plasma parameters approach the Lawson criterion for ignition. Power to drive the magnetic fields is frequently ignored in discussions of Q, with the justification that a steady-state, continuous-output fusion reactor will have superconducting magnet coils. (15 Dec 1997) |
| quality factor | <radiobiology> (Q) A multiplying factor used with absorbed dose to convert to dose equivalent and therefore to express the radiation's effectiveness in causing biological effects. (16 Dec 1997) |
| inhibition factor | <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence. It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated. Acronym: MIF Synonym: inhibition factor. (22 Sep 2002) |
| initiation factor | One of several soluble proteins involved in the initiation of protein or RNA synthesis. (05 Mar 2000) |
| insulin activating factor | <chemical> Activates insulin gene transcription in pancreatic beta cells. Synonym: insaf (05 Dec 1998) |
| insulin-antagonizing factor | A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect. Synonym: insulin-antagonizing factor. (05 Mar 2000) |
| insulin like growth factor | <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin. They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present). Insulin like growth factor I = somatomedin A = somatomedin C Insulin like growth factor II = MSA (Multiplication stimulating activity). Insulin like growth factor 1 is released from the liver in response to growth hormone. Acronym: IGF (18 Nov 1997) |
| insulin-like growth-factor binding protein 1 | One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29) (12 Dec 1998) |
| insulin-like growth factor-binding protein 2 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth factor binding protein 3 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin like growth-factor-binding protein 4 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding-protein 5 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |